We are live on ! Find out more
FC

Finepoint Capital Portfolio holdings

AUM $1.95B
1-Year Est. Return 45.61%
This Fund
S&P 500
This Quarter Est. Return
+4.05%
1 Year Est. Return
+45.61%
3 Year Est. Return
+24.83%
5 Year Est. Return
+26.66%
10 Year Est. Return
–
AUM
$262M
AUM Growth
-$47.5M
Cap. Flow
-$29.3M
Cap. Flow %
-11.2%
Top 10 Hldgs %
65.95%
Holding
44
New
1
Increased
12
Reduced
5
Closed
6

Top Buys

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$2.52M
2
RLAY icon
Relay Therapeutics
RLAY
+$2.36M
3
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$2.23M
4
ARVN icon
Arvinas
ARVN
+$1.98M
5
SLDB icon
Solid Biosciences
SLDB
+$1.62M

Top Sells

Rank Stock Value
1
ASTL icon
Algoma Steel
ASTL
+$20.4M
2
IOVA icon
Iovance Biotherapeutics
IOVA
+$9.88M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$4.96M
4
TVTX icon
Travere Therapeutics
TVTX
+$3.21M
5
APLS
Apellis Pharmaceuticals
APLS
+$2.95M

Sector Composition

Rank Sector Weight
1 Healthcare 99.25%
2 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TVTX icon
1
Travere Therapeutics
TVTX
$5.27B
$19.7M 7.52%
875,221
-151,079
-15% -$3.21M
APLS
2
DELISTED
Apellis Pharmaceuticals
APLS
$18.7M 7.15%
283,690
-51,200
-15% -$2.95M
ISEE
3
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$17.6M 6.72%
723,600
+16,000
+2% +$350K
ACAD icon
4
Acadia Pharmaceuticals
ACAD
$4.38B
$17.2M 6.59%
916,353
-260,477
-22% -$4.96M
LKFT
5
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.97B
$17.2M 6.56%
444,659
+54,300
+14% +$2.23M
SRPT icon
6
Sarepta Therapeutics
SRPT
$1.82B
$16.9M 6.46%
122,757
-8,700
-7% -$1.13M
ASND icon
7
Ascendis Pharma A/S
ASND
$17.1B
$16.7M 6.39%
156,072
+22,036
+16% +$2.52M
SAGE
8
DELISTED
Sage Therapeutics
SAGE
$16.3M 6.23%
388,865
+7,100
+2% +$305K
FOLD
9
DELISTED
Amicus Therapeutics
FOLD
$16.2M 6.19%
1,460,175
+31,700
+2% +$391K
PRTA icon
10
Prothena Corp
PRTA
$453M
$16.1M 6.14%
331,600
+8,700
+3% +$460K
SWTX
11
DELISTED
SpringWorks Therapeutics
SWTX
$15.8M 6.04%
614,231
-28,769
-4% -$841K
CYTK icon
12
Cytokinetics
CYTK
$10.9B
$14.6M 5.56%
413,793
+11,000
+3% +$449K
CRNX icon
13
Crinetics Pharmaceuticals
CRNX
$8.88B
$13.9M 5.33%
868,427
+45,682
+6% +$845K
RLAY icon
14
Relay Therapeutics
RLAY
$4.34B
$13.9M 5.32%
846,270
+131,422
+18% +$2.36M
ARVN icon
15
Arvinas
ARVN
$517M
$13.4M 5.14%
492,300
+62,700
+15% +$1.98M
CERE
16
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$13.2M 5.03%
539,445
+22,158
+4% +$650K
SLDB icon
17
Solid Biosciences
SLDB
$858M
$2.32M 0.89%
488,857
+270,295
+124% +$1.62M
AAC.WS
18
DELISTED
Ares Acquisition Corporation Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50
AAC.WS
$444K 0.17%
504,706
– –
HPLTW
19
DELISTED
Home Plate Acquisition Corporation Warrant
HPLTW
$219K 0.08%
690,000
– –
BTWNW
20
DELISTED
Bridgetown Holdings Limited Warrants
BTWNW
$134K 0.05%
895,000
– –
ROSS.WS
21
DELISTED
Ross Acquisition Corp II Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share
ROSS.WS
$115K 0.04%
439,666
– –
CPAAW
22
DELISTED
Conyers Park III Acquisition Corp. Warrants
CPAAW
$114K 0.04%
571,666
– –
CCV.WS
23
DELISTED
Churchill Capital Corp V Warrants, each exercisable for one share of Class A common stock at an exercise price of $11.50 per share
CCV.WS
$114K 0.04%
612,000
– –
GATEW
24
DELISTED
Marblegate Acquisition Corp. Warrant
GATEW
$110K 0.04%
735,000
– –
LSBPW
25
DELISTED
LakeShore Biopharma Warrants
LSBPW
$76.3K 0.03%
+489,999
New +$74.2K
1
2

Similar funds

NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
WPC
Waters Parkerson & Co New Orleans, Louisiana $1.95B AUM 15.9% 1-Year Est. Return
SGAM
Smith Group Asset Management Dallas, Texas $1.96B AUM 43.61% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
BC
Blackhill Capital Morristown, New Jersey $1.94B AUM 18.09% 1-Year Est. Return
FFH
Fairfax Financial Holdings Toronto, Ontario, Canada $1.94B AUM 27.76% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return

Finepoint Capital's Q1 2023 Portfolio in Review

As of Q1 2023, Finepoint Capital held 44 positions worth $262M, down 15% from $309M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Finepoint Capital withdrew a net $29.3M in Q1 2023, closing 6 positions and reducing 5 holdings. Its most notable exit was Algoma Steel, an estimated $20.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 90% a quarter earlier, followed by Materials.

Against the trend, Finepoint Capital opened a new position in LakeShore Biopharma Warrants worth $76.3K.

  • Finepoint Capital's largest Q1 2023 buy was LakeShore Biopharma Warrants: 489,999 shares worth $76.3K.
  • Finepoint Capital added most to Ascendis Pharma A/S in Q1 2023, an estimated $2.52M increase.
  • Finepoint Capital's biggest Q1 2023 reduction was Acadia Pharmaceuticals, cutting an estimated $4.96M.
  • Finepoint Capital fully exited Algoma Steel in Q1 2023, selling an estimated $20.4M.
  • Finepoint Capital's ten largest holdings make up 66% of its $262M portfolio in Q1 2023.
  • Finepoint Capital opened 1 new position and closed 6 in Q1 2023.
  • Finepoint Capital's portfolio value fell 15% quarter-over-quarter to $262M.

Based on Finepoint Capital's 13F filing for Q1 2023, filed 12 May 2023.